autologous anti-CD19 TAC-T cells TAC01-CD19

{
  "id": "MLC-T-ONC-011375",
  "term": "autologous anti-CD19 TAC-T cells TAC01-CD19",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes genetically engineered with a T cell Antigen Coupler (TAC), comprising of a domain that targets the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19) and another domain that binds to the endogenous T-cell receptor (TCR), anchored in the membrane via the CD4 co-receptor domain, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 TAC-T cells TAC01-CD19 targets and binds to CD19-expressing tumor cells and activates TCR-mediated signaling pathways, leading to T-cell-mediated killing of CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.",
  "synonyms": [
    "TAC01-CD19",
    "CD19-targeted T cell antigen coupler TAC01-CD19"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-cd19-tac-t-cells-tac01-cd19/"
}